Clinicopia Labeling On-Demand from InfoPro Solutions, Inc. Revolutionizes Clinical Labeling: Reducing Overall Costs and Increasing Quality Control
For the first time, midsize pharmaceutical and biotechnology companies engaged in clinical trials can cost effectively create, approve and print their labels in-house using InfoPro's Clinicopia Labeling On-Demand.
WESTLAKE VILLAGE, Calif., May 26, 2005 -- InfoPro Solutions, Inc. (www.infoprosolutions.com ) today announced Clinicopia Labeling On-Demand, a new hosted service accessed securely via the internet that delivers the full functionality and benefits of a clinical labeling system, without the time and costs associated with validating and deploying a new application in-house. Clinicopia Labeling on Demand revolutionizes clinical labeling by giving users in-house labeling functionality without an upfront investment.
"Clinicopia Labeling On-Demand is an essential tool for midsize pharmaceutical and biotechnology companies that may otherwise be burdened with print run minimums or large upfront investments," said Douglas Meyer, Senior Vice President, Pharmaceutical Science, at InfoPro Solutions. "With this solution these companies can bring their label development and printing in-house in the most economical way possible."
Clinicopia Labeling On-Demand provides the complete functionality needed to develop labels to be used on packages associated with clinical trials. Providing access via the internet, the solution gives users the ability to create, approve/reject and print labels all in a fully traceable process. Randomization numbers and other variable data can be integrated prior to final printing.
Compared to a "traditional" labeling system, Clinicopia Labeling on Demand lowers a company's start up and maintenance costs considerably. The end user is no longer responsible for many of the operational costs. The usage-based fee includes the use of the software, the associated support services, the use of the hardware and communications infrastructure, and all systems administration costs.
About InfoPro Solutions
Since 1995, InfoPro Solutions has been developing, implementing and maintaining enterprise-class, mission-critical information systems for the drug development markets within the pharmaceutical and biotechnology industries. InfoPro Solutions has developed numerous solutions in the clinical trials space to help their customers manage their extended supply chains. Clinicopia Suite is the world's first purpose built, industry specific Clinical Trials Supply Management Suite developed from the ground up. The On Demand services offer the full functionality and benefits of the Clinicopia Suite as a hosted service. InfoPro Solutions' list of customers includes AstraZeneca, Abbott Laboratories, Procter & Gamble, Chiron and Pfizer. InfoPro has offices in Los Angeles, Boston, Frankfurt and an offshore development center in Bangalore.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
